Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2013-08-13 Interim / Quarterly Rep…
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q2 2013
2013-08-13 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 7, 2013. It announces the proceeds received from the exercise of Series A Warrants by Actinium Pharmaceuticals, Inc. The content is a brief announcement of a financing event, specifically related to warrant exercise proceeds, and includes a press release as an exhibit. The document length is short (2406 characters), and it does not contain detailed financial statements or comprehensive financial analysis. Therefore, it is not an Annual Report, Interim Report, or Earnings Release. Instead, it is an update on a capital raising event. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP).
2013-06-07 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 31, 2013, reporting the termination of a consulting agreement and the resignation of a director, Dr. Rosemary Mazanet. It details management changes including resignation and compensatory arrangements related to the director's departure. The content focuses on board and management changes rather than financial results, audit information, or other report types. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4199 characters, which is typical for an 8-K filing of this nature and not a full annual or quarterly report. Hence, the classification is MANG with high confidence.
2013-05-31 English
FORM 4
Director's Dealing
2013-05-23 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2013
2013-05-15 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 11, 2013. It reports a corporate event: the change of domicile from Nevada to Delaware and a company name change from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. It includes exhibits such as certificates of incorporation, bylaws, and a press release. There are no financial statements or detailed financial data presented. The document is a regulatory announcement of a corporate change rather than a full financial report or earnings release. Given the nature of the filing and the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2013-04-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.